Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen | Zendy

Abdulla Salim Bin Ghouth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen

Author(s) -

Abdulla Salim Bin Ghouth

Publication year - 2013

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.2528

Subject(s) - lumefantrine , artesunate , malaria , artemether , medicine , medical prescription , artemether/lumefantrine , private sector , family medicine , chloroquine , sulfadoxine , intervention (counseling) , halofantrine , artemisinin , environmental health , mefloquine , pyrimethamine , pharmacology , nursing , economic growth , plasmodium falciparum , economics , immunology

Although the government of Yemen changed the national policy for treating malaria in November 2005 from chloroquine to combination drugs in the form of artesunate + sulphadoxine-pyrimethamine (SP) as first line and lumefantrine + artemether as second line treatment for uncomplicated malaria, clinicians in public and private health facilities continued to prescribe chloroquine because their knowledge about the new treatment policy was poor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research